1Bovill EG, Terrin ML, Stump DC ,et al. For the TIMI investigators hemorrhagic events during therapy with recombinant tissue type plasminogen activator, heparin and aspirin for acute myocardial infarction[J]. Ann Intern Med, 1991 ;115:256-65. 被引量：1
2The PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein Ⅱ b/Ⅲ a a receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction[J]. New Eng Med, 1998 ;338:1488-97. 被引量：1
3Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes:a collaborative meta-analysis of randomized trials[J]. JAMA ,2005 ;293:2908. 被引量：1
4Wamhohz A, Ostad MA, Heitzer T, et al. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J]. Am J Cardiol,2005 ;95 (1) :20-3. 被引量：1
5Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein Ⅱb/ Ⅲa. inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet,2002 ;359 (1) :189. 被引量：1
1STONE G W, MOLITERNO D J, BERTRAND M,et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein Ⅱb/Ⅲa in hibitors inpatients undergoing coronary stenting the TARGET trial[J]. Circulation, 2002,105 ：2345- 2354. 被引量：1
2CROUCH M A, NAPPI J M, CHEANG K I. Glycoprotein Ⅱb/Ⅲa receptor inbibitors in percutan coronary intervention and acute coronary syndrome [J].Ann Pharmacother, 2003, 37: 860-875. 被引量：1
3FUSTER V, BADIMON L, BADIMON J J, et al.The pathogenesis of coronary artery disease and the acute coronary syndromes [J]. N Engl J Med, 1992,326: 242- 250. 被引量：1
4The Restore Investigators. Effects of platelet Glycoprotein Ⅱb/Ⅲa Blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J]. Circulation ,1997, 96: 1445-1453. 被引量：1
5The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲ a receptor with tirofiban in unstable angina and non-Q-wave rnyocardial infarction[J]. N Engl J Med, 1998, 338:1488-1497. 被引量：1
6BOERSMA E, HARRINGTON R A, MOLITERNO D J, et al. Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet, 2002, 359:189-198. 被引量：1
7TCHENG J E, ELLIS S G, GEORGE B S, et al.Pharmacodynamics of chimetic glycoprotein Ⅱb/Ⅲa integrin antiplatelet antibody Fab TEs in high-risk coronary angioplasty[J]. Circulation, 1994, 90:1757-1764. 被引量：1
6Fung AY,Saw J,Starovoytov A,et al. Abbreviated infusion of ep-tifibatide after successful coronary intervention : the BRIEF-PCI (Brief Infusion of Eptiflbatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coil Cardiol,2009 ,53 (10): 837-845. 被引量：1
7Gibson CM,Ryan KA,Kelley M,et al.Methodologic drift in the assess-ment of TIMI grade 3 flow and its implications with respect to the repor-ting of angiographic trial results.The TIMI Study Group(J).Am Heart J,1999;137(6):1179-84. 被引量：1
8Gibson CM,Cannon CP,Murphy SA,et al.Relationship of TIMI myocar-dial perfusion grade to mortality after administration of thrombolytic drugs(J).Circulation,2000;101(2):125-30. 被引量：1
9Razakjr OA,Tan HC,Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coro-nary intervention(J).J Interv Cardiol,2005;18(1):33-7. 被引量：1
10ten Berg JM,van't Hof AW,Dill T,et al.Effect of early,pre-hospital ini-tiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short-and long-term clinical outcome(J).J Am Coll Cardiol,2010;55(22):2446-55. 被引量：1
